Leerink Partners upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a market perform rating to an ...

News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the second trading day of the week. The company posted its fourth-quarter ...

Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in ...

Regeneron (REGN) came out with quarterly earnings of $12.07 per share, beating the Zacks Consensus Estimate of $11.62 per share. This compares to earnings of $11.86 per share a year ago.

During the last three months, 18 analysts shared their evaluations of Regeneron Pharmaceuticals (NASDAQ:REGN), revealing diverse outlooks from bullish to bearish. The table below offers a ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, 2025. The Zacks Consensus Estimate for fourth-quarter revenues is pegged ...

REGENERON PHARMACEUTICALS ($REGN) posted quarterly earnings results on Tuesday, February 4th. The company reported earnings of $12.07 per share, beating estimates of ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

REGENERON PHARMACEUTICALS ($REGN) is expected to release its quarterly earnings data on Tuesday, February 4th before market open. Analysts are expecting revenue of ...

Regeneron Pharmaceuticals earnings at a glance ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Regeneron (REGN) reports results for the quarter ended December 2024. While this widely-known consensus outlook is ...

Regeneron (REGN) reported $3.79 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 10.3%. EPS of $12.07 for the same period compares to $11.86 a year ...